Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
•
Rheumatology
•
Discoid lupus
Is it safe to give radiation to a breast cancer patient with discoid lupus?
The patient has notable lip lesions from her discoid lupus erythematosus
Answer from: Radiation Oncologist at Community Practice
In published data with whole breast, it is well tolerated and we don’t consider this as a contraindication to BCT.
Sign in or Register to read more
15099
Related Questions
How would you approach management of a young male patient with discoid lupus who has had minimal response to hydroxychloroquine (and subtherapeutic whole blood levels) who continues to use tobacco products?
When do you consider the addition of concurrent pembrolizumab to breast irradiation?
When utilizing hypofractionated radiotherapy in the post mastectomy setting, are the nodal regions dose painted to a different dose or the same dose as the chest wall/reconstructed breast?
When should the dissected axilla (levels I-II) be included when delivering RNI?
How would you treat a perineural IgG4-RD with persistent paresthesia?
What fields would you treat for a postmastectomy patient with a single suspected small IMN node on MRI but no other criteria for PMRT and a negative SNB?
Should PMRT be offered for ypN0(i+) disease if only 1-2 nodes were removed in the post-chemotherapy SLNB and there is no plan for a completion AxLND?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
If a patient has multiple PET-avid level 3, supraclavicular, or IMN nodes that are small and would have been considered negative by size criteria with traditional imaging, that are no longer positive on PET after chemotherapy, would you try to boost these nodes?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?